Bladder Cancer
Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
December 31, 2024
The Financial Burden of Localized and Metastatic Bladder Cancer.
December 30, 2024
Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis.
December 30, 2024
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.
December 27, 2024
PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.
December 26, 2024
A novel smartphone application for bladder cancer management (BCM App): Design, development, and usability evaluation.
December 26, 2024
Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice.
December 25, 2024
Exploring the Immunoresponse in Bladder Cancer Immunotherapy.
December 25, 2024
Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial Carcinoma.
December 24, 2024
Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor.
December 23, 2024
FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
December 23, 2024
Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos.
December 20, 2024
Impact of immigration background on feasibility of electronic patient-reported outcomes in advanced urothelial cancer patients.
December 20, 2024
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
December 20, 2024
Prognostic Value of a B Cell Exhaustion Gene Signature in Bladder Cancer - Expert Commentary
December 19, 2024